Market Overview:
The global recombinant plasma proteins market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of hemophilia and von Willebrand disease, and rising demand for recombinant plasma proteins in emerging economies. The global recombinant plasma proteins market is segmented by type, application, and region. By type, the market is divided into Chinese hamster ovary (CHO) cell line, baby hamster kidney (BHK) cell line, human embryonic kidney (HEK) cell line, and others. The CHO cell line segment dominates the global recombinant plasma proteins market due to its high production efficiency and scalability. By application, the hemophilia A segment accounts for a major share of the global recombinant plasma proteins market owing to its high prevalence rate worldwide.
Product Definition:
Recombinant plasma proteins are proteins that are derived from recombinant DNA technology. These proteins can be used to treat a variety of medical conditions, including hemophilia, immunodeficiencies, and other diseases. Recombinant plasma proteins are important because they can help to improve the quality of life for people who suffer from these conditions.
Chinese Hamster Ovary (CHO) Cell Line:
CHO cell line is a mammalian fibroblast cell line that has been used as an expression system for the production of recombinant proteins. It was derived in 1970's from Chinese hamster ovary (CHO) cells by researchers at the University of Wisconsin-Madison. The primary function served by this cellular model is to study protein folding and its role in disease pathogenesis, which has led to extensive usage of these cells for research purposes over the past few decades.
Baby Hamster Kidney (BHK) Cell Line:
Baby hamster kidney (BHK) cell line is a human cell culture that has been derived from the placenta of day-old hamsters. The BHK cells have several unique properties, such as high proliferative ability, low immunogenicity, and high drug sensitivity. These cells are used for the production of recombinant proteins in large quantities and possess an excellent safety profile with no known drug resistance or toxicity issues.
Application Insights:
Based on the application, the global recombinant plasma proteins market is segmented into hemophilia A, B and other diseases. Hemophilia A held the largest share in terms of revenue in 2017 owing to increasing prevalence of this disease coupled with high treatment costs. For instance, as per U.S. National Library of Medicine National Institutes of Health (NIH), around 1,125 men were diagnosed with hemophilia in 2015 while around 1,250 were diagnosed with it a decade earlier in 2005.
The other diseases segment is anticipated to witness significant growth over forecast period due largely to rising incidences such as rheumatoid arthritis and osteoarthritis which are associated more commonly among people who have had blood transfusions or surgeries involving large amounts of blood loss during their lifetime thereby contributing towards overall demand for R&D products derived from these cell lines worldwide.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of pharmaceutical and biopharmaceutical companies, advanced healthcare infrastructure, favorable reimbursement policies for blood products, and increasing incidence rate of rare disorders are some factors driving the regional market.
Asia Pacific is expected to be the fastest-growing region during the forecast period owing to rising incidences of bleeding disorders such as hemophilia A & B in developing countries such as India and China. In addition, growing medical tourism industry due to low treatment cost is also anticipated to drive growth over this period. Increasing investments by governments in building up healthcare infrastructure will also boost growth over this period. For instance; In January 2018; Ministry Of Health And Family Welfare (MoHFW) Government Of India announced plan for establishment of 100 new centers across India with an investment worth USD X million under Pradhan Mantri Swasthya Suraksha Yojana (PMSSY).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to the World Health Organization (WHO), chronic diseases account for 60%–70% of all deaths worldwide. This number is expected to increase in the coming years due to the aging population and rising rates of obesity and diabetes. The growing incidence of chronic diseases will create a large demand for recombinant plasma proteins, which are used in the diagnosis and treatment of these conditions.
- Technological advancements: The recombinant plasma proteins market is witnessing rapid technological advancements, with new products being launched regularly by manufacturers. These products are helping healthcare professionals treat various medical conditions more effectively and improve patient outcomes significantly. Additionally, technological advances are also helping reduce costs associated with recombinant plasma protein therapies, thereby making them more affordable for patients around the world.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Plasma Proteins Market Research Report
By Type
Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Human Embryonic Kidney (HEK) Cell Line, Others
By Application
Hemophilia A, Hemophilia B, Von Willebrand Disease, Others
By Companies
CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Plasma Proteins Market Report Segments:
The global Recombinant Plasma Proteins market is segmented on the basis of:
Types
Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Human Embryonic Kidney (HEK) Cell Line, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hemophilia A, Hemophilia B, Von Willebrand Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Limited
- Shire (Takeda Pharmaceutical Company Limited)
- Octapharma
- Novo Nordisk
- Bayer
- Bioverativ Therapeutics, Inc. (Sanofi)
- Aptevo Therapeutics
- Pharming Group
- Pfizer
Highlights of The Recombinant Plasma Proteins Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chinese Hamster Ovary (CHO) Cell Line
- Baby Hamster Kidney (BHK) Cell Line
- Human Embryonic Kidney (HEK) Cell Line
- Others
- By Application:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Plasma Proteins Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant plasma proteins are proteins that have been created through the use of recombinant DNA technology. Recombinant plasma proteins are made from a variety of sources, including animal and human cells.
Some of the major players in the recombinant plasma proteins market are CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group, Pfizer.
The recombinant plasma proteins market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Plasma Proteins Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Plasma Proteins Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Plasma Proteins Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Plasma Proteins Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Plasma Proteins Market Size & Forecast, 2018-2028
4.5.1 Recombinant Plasma Proteins Market Size and Y-o-Y Growth
4.5.2 Recombinant Plasma Proteins Market Absolute $ Opportunity
Chapter 5 Global Recombinant Plasma Proteins Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Plasma Proteins Market Size Forecast by Type
5.2.1 Chinese Hamster Ovary (CHO) Cell Line
5.2.2 Baby Hamster Kidney (BHK) Cell Line
5.2.3 Human Embryonic Kidney (HEK) Cell Line
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Plasma Proteins Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Plasma Proteins Market Size Forecast by Applications
6.2.1 Hemophilia A
6.2.2 Hemophilia B
6.2.3 Von Willebrand Disease
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Plasma Proteins Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Plasma Proteins Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Plasma Proteins Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Plasma Proteins Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Plasma Proteins Market Size Forecast by Type
9.6.1 Chinese Hamster Ovary (CHO) Cell Line
9.6.2 Baby Hamster Kidney (BHK) Cell Line
9.6.3 Human Embryonic Kidney (HEK) Cell Line
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Plasma Proteins Market Size Forecast by Applications
9.10.1 Hemophilia A
9.10.2 Hemophilia B
9.10.3 Von Willebrand Disease
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Plasma Proteins Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Plasma Proteins Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Plasma Proteins Market Size Forecast by Type
10.6.1 Chinese Hamster Ovary (CHO) Cell Line
10.6.2 Baby Hamster Kidney (BHK) Cell Line
10.6.3 Human Embryonic Kidney (HEK) Cell Line
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Plasma Proteins Market Size Forecast by Applications
10.10.1 Hemophilia A
10.10.2 Hemophilia B
10.10.3 Von Willebrand Disease
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Plasma Proteins Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Plasma Proteins Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Plasma Proteins Market Size Forecast by Type
11.6.1 Chinese Hamster Ovary (CHO) Cell Line
11.6.2 Baby Hamster Kidney (BHK) Cell Line
11.6.3 Human Embryonic Kidney (HEK) Cell Line
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Plasma Proteins Market Size Forecast by Applications
11.10.1 Hemophilia A
11.10.2 Hemophilia B
11.10.3 Von Willebrand Disease
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Plasma Proteins Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Plasma Proteins Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Plasma Proteins Market Size Forecast by Type
12.6.1 Chinese Hamster Ovary (CHO) Cell Line
12.6.2 Baby Hamster Kidney (BHK) Cell Line
12.6.3 Human Embryonic Kidney (HEK) Cell Line
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Plasma Proteins Market Size Forecast by Applications
12.10.1 Hemophilia A
12.10.2 Hemophilia B
12.10.3 Von Willebrand Disease
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Plasma Proteins Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Plasma Proteins Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Plasma Proteins Market Size Forecast by Type
13.6.1 Chinese Hamster Ovary (CHO) Cell Line
13.6.2 Baby Hamster Kidney (BHK) Cell Line
13.6.3 Human Embryonic Kidney (HEK) Cell Line
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Plasma Proteins Market Size Forecast by Applications
13.10.1 Hemophilia A
13.10.2 Hemophilia B
13.10.3 Von Willebrand Disease
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Plasma Proteins Market: Competitive Dashboard
14.2 Global Recombinant Plasma Proteins Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL Limited
14.3.2 Shire (Takeda Pharmaceutical Company Limited)
14.3.3 Octapharma
14.3.4 Novo Nordisk
14.3.5 Bayer
14.3.6 Bioverativ Therapeutics, Inc. (Sanofi)
14.3.7 Aptevo Therapeutics
14.3.8 Pharming Group
14.3.9 Pfizer
